Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - asunaprevir -

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - lomustine, quantity: 10 mg - capsule, hard - excipient ingredients: mannitol; gelatin; titanium dioxide; magnesium stearate; indigo carmine; butan-1-ol; shellac; iron oxide black - (1) brain tumours (primary and secondary). (2) hodgkin's disease (as secondary therapy). lomustine is used in addition to appropriate surgical and/or radiotherapeutic procedures or as a component of various chemotherapeutic regimens in the palliative treatment of primary and metastatic brain tumours. ceenu containing combinations should be used as alternative therapy in the treatment of disseminated hodgkin's disease in patients refractory to other established treatment regimens.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - lomustine -

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - lomustine, quantity: 40 mg - capsule, hard - excipient ingredients: gelatin; indigo carmine; magnesium stearate; mannitol; titanium dioxide; iron oxide yellow; butan-1-ol; shellac; iron oxide black - (1) brain tumours (primary and secondary). (2) hodgkin's disease (as secondary therapy). lomustine is used in addition to appropriate surgical and/or radiotherapeutic procedures or as a component of various chemotherapeutic regimens in the palliative treatment of primary and metastatic brain tumours. ceenu containing combinations should be used as alternative therapy in the treatment of disseminated hodgkin's disease in patients refractory to other established treatment regimens.

Egypt - English - EDA (Egyptian Drug Authority)

bristol-myers squibb-egypt - capsule - 400 i.u.

United States - English - NLM (National Library of Medicine)

bristol-myers squibb/sanofi pharmaceuticals partnership - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel 75 mg - - plavix is indicated to reduce the rate of myocardial infarction (mi) and stroke in patients with non–st-segment elevation acs (unstable angina [ua]/non–st-elevation myocardial infarction [nstemi]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. plavix should be administered in conjunction with aspirin. - plavix is indicated to reduce the rate of myocardial infarction and stroke in patients with acute st-elevation myocardial infarction (stemi) who are to be managed medically. plavix should be administered in conjunction with aspirin. in patients with established peripheral arterial disease or with a history of recent myocardial infarction (mi) or recent stroke plavix is indicated to reduce the rate of mi and stroke. plavix is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. plavix is contraindicated in patients with hypersensitivity (e.g., anaphylaxis) to clopidogrel or any comp

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - abatacept 262.5mg;  ;   - powder for injection - 250 mg - active: abatacept 262.5mg     excipient: hydrochloric acid maltose monobasic sodium phosphate dihydrate sodium chloride sodium hydroxide - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an insufficient response or intolerance to other disease modifying anti-rheumatic drugs (dmards), such as methotrexate or tumour necrosis factor (tnf) blocking agents. a reduction in the progression of joint damage and improvement in physical function have been demonstrated during combination treatment with orencia and methotrexate. orencia in combination with methotrexate is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. orencia is indicated for reducing signs and symptoms in paediatric patients 6 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). orencia may be used concomitantly with methotrexate (mtx). (there is no clinical trial data for the use of orencia subcutaneous formulation in children, therefore its use in children cannot be recommended.) orencia should not be administered concurrently with other biological dmards (eg, tnf inhibitors, rituximab, or anakinra).

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - abatacept 125.875mg equivalent to abatacept 125mg/ml;  ;   - solution for injection - 125 mg - active: abatacept 125.875mg equivalent to abatacept 125mg/ml     excipient: dibasic sodium phosphate monobasic sodium phosphate nitrogen poloxamer 188 sucrose water for injection - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an insufficient response or intolerance to other disease modifying anti-rheumatic drugs (dmards), such as methotrexate or tumour necrosis factor (tnf) blocking agents. a reduction in the progress of joint damage and improvement in physical function have been demonstrated during combination treatment with orencia and methotrexate. orencia in combination with methotrexate is also indicated in the treatment of severe, active and progressive rheumatoid arthiritis in adults not previously treated with methotrexate. orencia should not be administered concurrently with other dmards (eg. tnf inhibitors, rituximab or anakinra).

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - didanosine 125mg;   - capsule - 125 mg - active: didanosine 125mg   excipient: carmellose sodium diethyl phthalate gelatin methacrylic acid copolymer purified talc sodium starch glycolate tekprint tan sw-8010 titanium dioxide - videx ec in combination with other antiretroviral drugs, is indicated for the treatment of hiv infected adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - didanosine 200mg;   - capsule - 200 mg - active: didanosine 200mg   excipient: carmellose sodium diethyl phthalate gelatin methacrylic acid copolymer purified talc sodium starch glycolate tekprint green sb-4020 titanium dioxide - videx ec in combination with other antiretroviral drugs, is indicated for the treatment of hiv infected adults.